<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00837616</url>
  </required_header>
  <id_info>
    <org_study_id>908-M01</org_study_id>
    <nct_id>NCT00837616</nct_id>
  </id_info>
  <brief_title>Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism</brief_title>
  <official_title>Estrogen Dosing in Turner Syndrome:Pharmacology &amp; Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nemours Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nemours Children's Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Estrogen is necessary for feminization during puberty and to decrease bone resorption, the
      latter critical for the achievement of peak bone mass and normal bone health in the female.
      The practicing pediatric endocrinologist often faces the dilemma of how to best feminize
      girls with hypogonadism (lack of estrogen), manifested as delayed or arrested puberty, due to
      disorders of the brain or the ovaries. We propose a series of studies to address which type,
      dose, and route of delivery of estrogen are suitable choices in feminizing and sustaining
      estrogen concentrations in adolescent girls with Turner syndrome. To accomplish this we will
      study girls/young woman between the ages of 13 to 20 with Turner Syndrome in 2 protocols. In
      Protocol # 1 we will study 24 girls with TS, they will receive 3 different estrogen
      preparations, either by mouth or via a patch for a total of 6 weeks. They will come to the
      clinical research center for blood draws after 2 wks of taking the estrogen. With this study,
      we hope to learn how the body responds to estrogen differently, depending on the form
      estrogen is given and how high, estrogen levels gets in the blood in these girls with Turner
      Syndrome. We will be comparing these patients estrogen levels to girls that menstruate
      normally and do not have Turner Syndrome. In Protocol #2, 40 patients with TS will be
      recruited; these patients will take estrogen for 1 year, either by mouth or via a patch.
      Patients will come to the lab for blood drawn in 7 occasions and we will measure estrogen
      levels as well as other hormones and lipid levels. We will also perform a Dual-energy X-ray
      absorptiometry (DXA) study (like an X ray) to assess body composition and bone
      mineralization. We will adjust doses based on the estrogen levels we find. With this study we
      hope to learn how estrogen affects body composition, i.e., the amount of fat vs. muscle, and
      how different forms of estrogen affect blood cholesterol and other hormones. This study will
      allow us to understand better how to best replace young woman with Turner Syndrome with
      estrogen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data on the specific effects and bioequivalency of the different forms of estrogen are
      lacking, and in the young adolescent age group in particular, virtually non-existent. This
      has been complicated further by the difficulty in accurately interpreting estradiol assay
      results as the conventional radioimmunoassays (RIA) for estradiol are inaccurate and
      insensitive measuring very small concentrations in plasma. There is wide variation in the
      types of estrogens used for estrogen replacement, as well as doses and route of
      administration. Girls with Turner syndrome (TS) represent an important case study for these
      issues as they have early primary gonadal insufficiency or failure many years before the
      achievement of peak bone mass. Hence, a study of the effects of different estrogen compounds
      in this patient population offers a unique model that eliminates the confounding effects of
      other products produced by the intact gonad. Since in this condition it is imperative that
      estrogen replacement is started during the adolescent years and continued for several
      decades, this issue becomes highly relevant to these young women's health.Our specific aims
      are to: 1. to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) and relative
      biological potency of different oral vs. transdermal preparations of estradiol using
      state-of-the-art tandem mass spectrometry assays and recombinant cell bioassays; 2. to
      investigate the differential, long term metabolic effects of oral vs. transdermal estrogen
      replacement, specifically the effects on lipid and protein metabolism as well as body
      composition in this patient population; 3. to determine feasibility of estrogen
      concentration-based dosing in puberty and 4. To characterize the metabolic profile of TS
      girls previously treated with GH. To accomplish this we will study girls/young woman between
      ages 13 to 20 with TS in 2 protocols. Protocol #1 will be a study of the
      pharmacokinetic/pharmacodynamic (PK/PD) of 3 different preparations of estrogen in different
      doses. Protocol #2 will be a one year longitudinal study of the effects of oral vs.
      transdermal (TD) estrogen on body composition, hormones and growth factors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Weight From Baseline at 12 Months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Body Mass Index From Baseline at 12 Months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Percent Fat Mass From Baseline in 12 Months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fat Free Mass From Baseline at 12 Months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize PK/PD and Relative Biological Potency of Different Oral vs TD Estrogen Preparations</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Insulin Growth Factor-I From Baseline at 12 Months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Lipid Oxidation After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum 17B Estradiol Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Estrone Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Estrone Sulfate Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Turner Syndrome</condition>
  <condition>Hypogonadism</condition>
  <condition>Premature Ovarian Failure</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A will receive the oral estradiol for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B will receive the transdermal estradiol for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17 B estradiol orally</intervention_name>
    <description>Group A will be given estrogen by mouth daily(0.5 mg or 1mg or 2 mg of 17B Estradiol. Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Estrace</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17 B estradiol</intervention_name>
    <description>Group B will be given estrogen via a patch applied to the skin twice a week (0.375mg or 0.05mg or 0.075mg) Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Vivelle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Girls with Turner Syndrome (45X, or related karyotypes) diagnosed clinically and
             cytogenetically

          -  Female subjects with Y material will be allowed providing gonadectomies have been
             performed previously

          -  Age: 13-20 years

          -  Subjects have completed or nearly completed their linear growth

          -  Previous growth hormone (GH) therapy discontinued at least 6 months prior to study
             participation

          -  Stable thyroid replacement therapy will be allowed

          -  Celiac disease on stable diets will be allowed

          -  Any previous hormone replacement therapy (HRT) will be allowed

        Exclusion Criteria:

          -  Diabetes Mellitus on insulin therapy, insulin sensitizers or oral hypoglycemics

          -  Inflammatory Bowel Disease (ulcerative colitis or Crohn's disease), celiac disease

          -  Cigarette smoking

          -  Any other chronic conditions, that, in the opinion of investigators could impair the
             metabolism of nutrients

          -  Severe obesity, i.e., Body Mass Index (BMI) &gt;95th centile
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelly Mauras, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemours Children's Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jefferson Medical College of Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chile/Clinica las Condes</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hgf.org</url>
  </link>
  <results_reference>
    <citation>Torres-Santiago L, Mericq V, Taboada M, Unanue N, Klein KO, Singh R, Hossain J, Santen RJ, Ross JL, Mauras N. Metabolic effects of oral versus transdermal 17β-estradiol (E₂): a randomized clinical trial in girls with Turner syndrome. J Clin Endocrinol Metab. 2013 Jul;98(7):2716-24. doi: 10.1210/jc.2012-4243. Epub 2013 May 15.</citation>
    <PMID>23678038</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2009</study_first_submitted>
  <study_first_submitted_qc>February 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2009</study_first_posted>
  <results_first_submitted>May 28, 2013</results_first_submitted>
  <results_first_submitted_qc>December 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2014</results_first_posted>
  <last_update_submitted>February 26, 2014</last_update_submitted>
  <last_update_submitted_qc>February 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nemours Children's Clinic</investigator_affiliation>
    <investigator_full_name>Nelly Mauras</investigator_full_name>
    <investigator_title>Chief, Division of Endocrinology, Diabetes &amp; Metabolism</investigator_title>
  </responsible_party>
  <keyword>Turner Syndrome</keyword>
  <keyword>Hypogonadism</keyword>
  <keyword>GH</keyword>
  <keyword>Estrogen</keyword>
  <keyword>Estrogen Patches</keyword>
  <keyword>IGF-I</keyword>
  <keyword>Body Composition</keyword>
  <keyword>Protein Metabolism</keyword>
  <keyword>Lipid Oxidation</keyword>
  <keyword>Estradiol assay by LCMSMS</keyword>
  <keyword>Recombinant Cell Bioassay</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Turner Syndrome</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Forty-one girls with Turner Syndrome (45X and related karyotypes), between 13 and 20 years were recruited and followed among the 3 participating centers at the Nemours Children’s Clinic, Jacksonville (coordinating center), Nemours Jefferson, and Clínica las Condes/University of Chile, Santiago, Chile.</recruitment_details>
      <pre_assignment_details>Any previous growth hormone (GH) therapy was discontinued at least 6 months prior to study participation. Estrogen replacement therapy was discontinued for at least 6 weeks prior to baseline studies. Subjects with significant obesity (BMI &gt; 36 kg/m2) or history of systemic illness were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Estradiol</title>
          <description>Group A received the oral estradiol for 12 months</description>
        </group>
        <group group_id="P2">
          <title>Transdermal Estradiol</title>
          <description>Group B received the transdermal estradiol for 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>Group A received the oral estradiol for 12 months</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>Group B received the transdermal estradiol for 12 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.7" spread="1.7"/>
                    <measurement group_id="B2" value="16.7" spread="1.8"/>
                    <measurement group_id="B3" value="16.7" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Weight From Baseline at 12 Months</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Estradiol</title>
            <description>Group A received the oral estradiol for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Transdermal Estradiol</title>
            <description>Group B received the transdermal estradiol for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight From Baseline at 12 Months</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.6"/>
                    <measurement group_id="O2" value="1.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Insulin Growth Factor-I From Baseline at 12 Months</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Estradiol</title>
            <description>Group A received the oral estradiol for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Transdermal Estradiol</title>
            <description>Group B received the transdermal estradiol for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Insulin Growth Factor-I From Baseline at 12 Months</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16" spread="12"/>
                    <measurement group_id="O2" value="28" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipids Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Estradiol</title>
            <description>Group A received the oral estradiol for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Transdermal Estradiol</title>
            <description>Group B received the transdermal estradiol for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Lipids Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" spread="7"/>
                    <measurement group_id="O2" value="153" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Density Lipoprotein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" spread="4"/>
                    <measurement group_id="O2" value="88" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Density Lipoprotein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" spread="3"/>
                    <measurement group_id="O2" value="50" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" spread="19"/>
                    <measurement group_id="O2" value="70" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Lipid Oxidation After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Estradiol</title>
            <description>Group A received the oral estradiol for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Transdermal Estradiol</title>
            <description>Group B received the transdermal estradiol for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Lipid Oxidation After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months</title>
          <units>Kcal/Fat Free Mass/day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="2.8"/>
                    <measurement group_id="O2" value="7.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum 17B Estradiol Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Estradiol</title>
            <description>Group A received the oral estradiol for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Transdermal Estradiol</title>
            <description>Group B received the transdermal estradiol for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum 17B Estradiol Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" spread="19"/>
                    <measurement group_id="O2" value="74" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Body Mass Index From Baseline at 12 Months</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Estradiol</title>
            <description>Group A received the oral estradiol for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Transdermal Estradiol</title>
            <description>Group B received the transdermal estradiol for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index From Baseline at 12 Months</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.075" spread="0.38"/>
                    <measurement group_id="O2" value="0.65" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Percent Fat Mass From Baseline in 12 Months</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Estradiol</title>
            <description>Group A received the oral estradiol for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Transdermal Estradiol</title>
            <description>Group B received the transdermal estradiol for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Fat Mass From Baseline in 12 Months</title>
          <units>percent fat mass</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.56"/>
                    <measurement group_id="O2" value="-0.64" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Fat Free Mass From Baseline at 12 Months</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Estradiol</title>
            <description>Group A received the oral estradiol for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Transdermal Estradiol</title>
            <description>Group B received the transdermal estradiol for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fat Free Mass From Baseline at 12 Months</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.37"/>
                    <measurement group_id="O2" value="1.67" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characterize PK/PD and Relative Biological Potency of Different Oral vs TD Estrogen Preparations</title>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Estrone Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Estradiol</title>
            <description>Group A received the oral estradiol for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Transdermal Estradiol</title>
            <description>Group B received the transdermal estradiol for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Estrone Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="504" spread="80"/>
                    <measurement group_id="O2" value="43" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Estrone Sulfate Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Estradiol</title>
            <description>Group A received the oral estradiol for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Transdermal Estradiol</title>
            <description>Group B received the transdermal estradiol for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Estrone Sulfate Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63638" spread="21088"/>
                    <measurement group_id="O2" value="1875" spread="414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>Group A received the oral estradiol for 12 months</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>Group B received the transdermal estradiol for 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nelly Mauras</name_or_title>
      <organization>Nemours Children's Clinic</organization>
      <phone>(904) 697-3674</phone>
      <email>nmauras@nemours.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

